EBA
CRSP icon

Eagle Bay Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Eagle Bay Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300
Closed -$23K – 441
2021
Q4 		$23K Buy
+300
New +$26.2K 0.01% 533

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eagle Bay Advisors's CRSP Position: Q1 2022 in Review

Eagle Bay Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 300 shares — an estimated $23K sold.

Eagle Bay Advisors first reported a position in CRSP in Q4 2021 and held it in 1 quarter. The position peaked at $23K in Q4 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

  • Eagle Bay Advisors reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Eagle Bay Advisors sold 300 CRISPR Therapeutics shares in Q1 2022, an estimated $23K.
  • Eagle Bay Advisors first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 1 quarter.
  • Eagle Bay Advisors's CRISPR Therapeutics position peaked at $23K in Q4 2021.
  • 447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.